These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22911289)

  • 21. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine.
    Robbins RJ; Driedger A; Magner J;
    Thyroid; 2006 Nov; 16(11):1121-30. PubMed ID: 17123339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
    Berg G; Lindstedt G; Suurküla M; Jansson S
    J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interrupted 131I Procedures for Patients With Differentiated Thyroid Cancer: Comparing Thyroxine Withdrawal With Recombinant Thyrotropin Preparation Techniques.
    Karls S; Abikhzer G; Tamilia M; Probst S
    Clin Nucl Med; 2017 Apr; 42(4):247-249. PubMed ID: 28166158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
    Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
    de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
    J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation.
    Lin JD; Chao TC; Huang MJ; Weng HF; Tzen KY
    Am J Clin Oncol; 1998 Feb; 21(1):77-81. PubMed ID: 9499265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
    Pacini F; Castagna MG
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
    Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
    Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?
    Pitoia F; Degrossi OJ; Niepomniszcze H
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31(6):924; author reply 924-5. PubMed ID: 15034676
    [No Abstract]   [Full Text] [Related]  

  • 32. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
    De Klerk JM; Oyen WJ
    Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
    Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma.
    Pitoia F; El Tamer E; Salvai ME; Niepomniszcze H
    Medicina (B Aires); 2009; 69(1 Pt 2):148-52. PubMed ID: 19414296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.
    Sgouros G
    J Nucl Med; 2005 May; 46(5):899-900; author reply 901. PubMed ID: 15872367
    [No Abstract]   [Full Text] [Related]  

  • 37. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
    Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production.
    Luster M; Reinhardt W; Korber C; Lassmann M; Haenscheid H; Michalowski U; Rendl J; Eising E; Mann K; Reiners C
    J Endocrinol Invest; 2000; 23(7):473-5. PubMed ID: 11005273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
    Kohlfuerst S; Igerc I; Lind P
    Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.